Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Hikal is currently trading at Rs. 409.95, up by 13.20 points or 3.33% from its previous closing of Rs. 396.75 on the BSE.
The scrip opened at Rs. 409.95 and has touched a high and low of Rs. 420.00 and Rs. 405.50 respectively. So far 3,909 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 517.85 on 31-Dec-2012 and a 52 week low of Rs. 263.25 on 05-Jun-2012.
The current market cap of the company is Rs. 673.00 crore.
The promoters holding in the company stood at 68.82%, while Institutions and Non-Institutions held 6.16% and 25.01% respectively.
Hikal’s second manufacturing facility located at Panoli, Bharuch district in the state of Gujarat, which manufactures pharmaceutical ingredients, intermediates and regulated starting materials has successfully completed a USFDA audit and received the approval. The company has already received USFDA approval for its pharmaceutical intermediates and active pharma ingredients (API's) manufacturing site located in Jigani, Bengaluru in Karnataka state.
This additional site approval will further add to capacities, which is beneficial to its customers. It will mitigate the risk of supply by having two sites certified by the USFDA. The additional site certification is a true testimony to the high standards of quality, regulatory compliance and operating standards at Hikal.
Both the sites have multipurpose facilities and capabilities which support the company’s global customers. The pharmaceutical division is supported by 2 R&D centres based in Bangalore and Pune, India where they provide early stage research services, new product development all the way to successful commercialization. The API manufacturing site at Bangalore has been inspected 3 times by the USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1455.00 |
| Dr. Reddys Lab | 5730.85 |
| Cipla | 1459.75 |
| Zydus Lifesciences | 1007.20 |
| Lupin | 1564.60 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
